Preventive or therapeutic agent for fibrosis


Ontology type: sgo:Patent     


Patent Info

DATE

N/A

AUTHORS

Esteban C Gabazza , Tetsu Kobayashi , Hidekazu Toyobuku , Ayako Fukuda , Tetsuya Hasegawa

ABSTRACT

Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3197", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "Esteban C Gabazza", 
        "type": "Person"
      }, 
      {
        "name": "Tetsu Kobayashi", 
        "type": "Person"
      }, 
      {
        "name": "Hidekazu Toyobuku", 
        "type": "Person"
      }, 
      {
        "name": "Ayako Fukuda", 
        "type": "Person"
      }, 
      {
        "name": "Tetsuya Hasegawa", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.bjps.2006.05.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001973825"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.gt.3302480", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013530346", 
          "https://doi.org/10.1038/sj.gt.3302480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-4604", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024348606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.yexmp.2005.11.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025026755"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/nar/gkn042", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029586921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10529-005-2516-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050051106", 
          "https://doi.org/10.1007/s10529-005-2516-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1615/jenvironpatholtoxicoloncol.v28.i2.30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068146425"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "description": "

Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1.

", "id": "sg:patent.US-8772262-B2", "keywords": [ "therapeutic agent", "fibrosis", "Small Interfering RNA", "siRNAs", "full length", "nucleotide", "sequence", "base", "ID" ], "name": "Preventive or therapeutic agent for fibrosis", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.260026.0", "type": "Organization" }, { "id": "https://www.grid.ac/institutes/grid.419953.3", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-8772262-B2" ], "sdDataset": "patents", "sdDatePublished": "2019-03-07T15:34", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com.uberresearch.data.dev.patents-pipeline/full_run_10/sn-export/5eb3e5a348d7f117b22cc85fb0b02730/0000100128-0000348334/json_export_b65d5aab.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-8772262-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-8772262-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-8772262-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-8772262-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

71 TRIPLES      14 PREDICATES      30 URIs      16 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-8772262-B2 schema:about anzsrc-for:3197
2 schema:author N5dbe9a7a0f5e494baa185d553c6efe12
3 schema:citation sg:pub.10.1007/s10529-005-2516-0
4 sg:pub.10.1038/sj.gt.3302480
5 https://doi.org/10.1016/j.bjps.2006.05.007
6 https://doi.org/10.1016/j.yexmp.2005.11.005
7 https://doi.org/10.1093/nar/gkn042
8 https://doi.org/10.1158/1078-0432.ccr-07-4604
9 https://doi.org/10.1615/jenvironpatholtoxicoloncol.v28.i2.30
10 schema:description <p num="p-0001">Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1.</p>
11 schema:keywords ID
12 Small Interfering RNA
13 base
14 fibrosis
15 full length
16 nucleotide
17 sequence
18 siRNAs
19 therapeutic agent
20 schema:name Preventive or therapeutic agent for fibrosis
21 schema:recipient https://www.grid.ac/institutes/grid.260026.0
22 https://www.grid.ac/institutes/grid.419953.3
23 schema:sameAs https://app.dimensions.ai/details/patent/US-8772262-B2
24 schema:sdDatePublished 2019-03-07T15:34
25 schema:sdLicense https://scigraph.springernature.com/explorer/license/
26 schema:sdPublisher N3314a76bfb634a70a97e5621171ee35d
27 sgo:license sg:explorer/license/
28 sgo:sdDataset patents
29 rdf:type sgo:Patent
30 N32f0a0e4384e43888505edb1fb5a9375 schema:name Tetsuya Hasegawa
31 rdf:type schema:Person
32 N3314a76bfb634a70a97e5621171ee35d schema:name Springer Nature - SN SciGraph project
33 rdf:type schema:Organization
34 N469971fae91340d8a365a12b4bfc8f04 rdf:first Nc5f2326300fe4b6f81bdd432608dc978
35 rdf:rest N8432c0739b6940bb901678718380b413
36 N5dbe9a7a0f5e494baa185d553c6efe12 rdf:first Na77d636dd97c457c8a45068f7c178581
37 rdf:rest Nbeecee1851574aab8dc171725a62841d
38 N78af9a24a3974e1d86b52b09366e2422 rdf:first N32f0a0e4384e43888505edb1fb5a9375
39 rdf:rest rdf:nil
40 N8432c0739b6940bb901678718380b413 rdf:first Na2f42e3e61f84fc2a0da08a1b1503d4f
41 rdf:rest N78af9a24a3974e1d86b52b09366e2422
42 Na2f42e3e61f84fc2a0da08a1b1503d4f schema:name Ayako Fukuda
43 rdf:type schema:Person
44 Na77d636dd97c457c8a45068f7c178581 schema:name Esteban C Gabazza
45 rdf:type schema:Person
46 Nbeecee1851574aab8dc171725a62841d rdf:first Nc375200d56644a9ca04863fd1812aa85
47 rdf:rest N469971fae91340d8a365a12b4bfc8f04
48 Nc375200d56644a9ca04863fd1812aa85 schema:name Tetsu Kobayashi
49 rdf:type schema:Person
50 Nc5f2326300fe4b6f81bdd432608dc978 schema:name Hidekazu Toyobuku
51 rdf:type schema:Person
52 anzsrc-for:3197 schema:inDefinedTermSet anzsrc-for:
53 rdf:type schema:DefinedTerm
54 sg:pub.10.1007/s10529-005-2516-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050051106
55 https://doi.org/10.1007/s10529-005-2516-0
56 rdf:type schema:CreativeWork
57 sg:pub.10.1038/sj.gt.3302480 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013530346
58 https://doi.org/10.1038/sj.gt.3302480
59 rdf:type schema:CreativeWork
60 https://doi.org/10.1016/j.bjps.2006.05.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001973825
61 rdf:type schema:CreativeWork
62 https://doi.org/10.1016/j.yexmp.2005.11.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025026755
63 rdf:type schema:CreativeWork
64 https://doi.org/10.1093/nar/gkn042 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029586921
65 rdf:type schema:CreativeWork
66 https://doi.org/10.1158/1078-0432.ccr-07-4604 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024348606
67 rdf:type schema:CreativeWork
68 https://doi.org/10.1615/jenvironpatholtoxicoloncol.v28.i2.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068146425
69 rdf:type schema:CreativeWork
70 https://www.grid.ac/institutes/grid.260026.0 schema:Organization
71 https://www.grid.ac/institutes/grid.419953.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...